A Blood Test To Detect CTE in living NFL players

A man who leads a medical company in San Diego is working on a blood test to determine if someone has chronic tramautic encephalopathy, or CTE. 

Right now, CTE can only be found during an autopsy, as was the case of Junior Seau. 

Jim Joyce who once played for the Denver Broncos has been working on the test at his company, Aethlon Medical in San Diego, since his friend and former player, Tom McHale passed away from CTE in 2009.

That's when, he started working with the Boston University CTE center to look for a biomarker that could identify people with CTE in living individuals.

Joyce tells KOGO News in recent years they've demonstrated a high correlation between cognitive decline and levels of the bio marker,  and they've determined the biomarker in former NFL players is much higher in blood than compared to controlled subjects.

Joyce says the goal is to get a blood test for people who are living. It could also possibly be used to detect Alzheimer's and then early treatment could begin.

Read more BELOW.

Researchers with Exosome Sciences, Inc., a diagnostic subsidiary of Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company, today announced plans to initiate a clinical study involving retired NFL players and a data-supported biomarker candidate to detect and monitor Chronic Traumatic Encephalopathy (CTE) in living individuals. CTE is a neurodegenerative disease that has often been found in American football players, boxers and other individuals with a history of repetitive head trauma. At present, CTE diagnosis is determined after death through an analysis of brain tissue. 

Planned for initiation in the second quarter, the study intends to establish a clinical collaboration with up to 200 former professional football players and clinical investigators at multiple U.S. locations. If fully enrolled, the study would be the largest to date in former NFL players, who are at a high risk of suffering from CTE. The goal of the study will be to further validate a CTE biomarker candidate known as plasma exosomal tau, or a TauSome™. The biomarker was previously studied as part of the first NIH-funded CTE research program (The DETECT Study), which was managed by the Boston University (BU) CTE Center. 

Kendall Van Keuren-Jensen, Ph.D., Co-Director of the Translational Genomics Research Institute's (TGen) Center for Noninvasive Diagnostics in Phoenix, will serve as principal investigator for the study. Dr. Van Keuren-Jensen is neurodegenerative disease thought leader whose research includes discovery and detection of biomarkers for central nervous system disorders. 

"This study provides researchers an opportunity to potentially change how doctors diagnose CTE, which today can only be diagnosed post-mortem," said Dr. Van Keuren-Jensen. "Validating plasma exosomal tau as the basis for a non-invasive test to detect and monitor CTE in living individuals will expand significantly the body of clinical data available for analysis and may provide a starting point for early intervention." 

In the previous DETECT Study, researchers examined 78 former NFL players and a control group of 16 former non-contact sport athletes. The researchers observed that plasma TauSome levels were significantly elevated in the NFL group as compared to the control group and that, within the former NFL player group, TauSome plasma levels correlated with performance on standardized tests of memory and psychomotor speed; the higher the TauSome level, the worse the performance. The preliminary results were subsequently published in the Journal of Alzheimer's Disease. Access to the online version of the publication is available at http://tinyurl.com/zvyd23h. Based on these preliminary findings, the authors concluded that TauSome levels in blood plasma could be an accurate, noninvasive CTE biomarker. Since the publication, an ongoing analysis of the study data revealed that TauSome levels were approximately 9x higher on average in the NFL group as compared to control subjects. 

Jim Joyce, Chairman and CEO of Aethlon Medical, Founder of Exosome Sciences and a former professional football player, said, "Our goal is to collect further evidence that supports the possibility that CTE can be diagnosed in the living. If the studies are successful, the door then opens for therapeutic candidates to be tested against this horrific disease that has impacted the lives of former players and their families. The original inspiration for our research was the death of Tom McHale, a former teammate who was also from my hometown in Maryland. It was at Super Bowl XLIII in 2009 that researchers from the BU team announced that Tom had suffered from CTE when he died at the age of 45. Therefore, in the week leading up to Super Bowl LI in Houston, we will conduct a series of activities to raise awareness of the current study plans among prospective participants." 

Activities planned for Houston include Joyce's participation in the Global Brain Health Coalition's annual meeting as well as interviews on Super Bowl Radio Row. In addition, the Aethlon/Exosome Sciences team will be hosting informal discussions with former playersabout the establishment of an advisory council. To schedule a meeting, contact Charlene Owen at Aethlon Medical at 858-251-1848 or via email at cowen@aethlonmedical.com. 

Joyce concluded: "We are grateful for the opportunity that was provided though the BU DETECT study to gather evidence that TauSome plasma levels may serve as a biomarker to detect CTE. Beyond the advancement of our new study, we have agreed to provide continued TauSome analysis to support the clinical initiatives of our colleague at BU." 

In addition to CTE, the researchers plan to investigate the potential for TauSome plasma levels to serve as a biomarker to monitor Alzheimer's disease and other neurological diseases that involve the abnormal aggregation of tau protein in the brain. 

About Exosomes Exosomes are very small vesicles released from all types of cells throughout the body, including brain cells. They can be isolated in all body fluids, including plasma, a component of blood. Exosomes carry within them the proteins from their cells of origin. Because exosomes can cross the blood-brain-barrier (a selective barrier that separates the circulating blood from the brain's extracellular fluid), they can provide a unique method of measuring certain aspects of the contents of brain cells through a blood test. 

That is, if the brain-derived exosomes can be isolated in plasma and then be stained for specific proteins found in the brain cells, researchers can potentially measure brain proteins through a blood test. About Exosome Sciences Exosome Sciences, Inc., in collaboration with majority shareholder Aethlon Medical (Nasdaq: AEMD), is focused on discovering exosomal biomarkers to diagnose and monitor Alzheimer's disease (AD), Chronic Traumatic Encephalopathy (CTE) and other neurological disorders. Our TauSome™ biomarker (also referred to as exosomal tau) is being clinically evaluated as the basis for a blood-based test to identify CTE in living individuals. Visit www.exosomesciences.com for additional details. 

About Aethlon Medical, Inc. Aethlon Medical (Nasdaq: AEMD) is a leading developer of immunotherapeutic technologies to combat infectious disease and cancer. The Aethlon Hemopurifier® is a first-in-class medical technology currently being advanced in FDA approved studies as a broad-spectrum treatment countermeasure against infectious viral pathogens. Named a "Top 25 Invention" and one of the "Eleven Most Remarkable Advances in Healthcare," by TIME Magazine, the Hemopurifier® has previously been administered to individuals infected with Ebola virus, Hepatitis C virus and the Human Immunodeficiency virus. Aethlon is also the majority owner of Exosome Sciences, Inc., a company focused on the discovery of exosomal biomarkers to diagnose and monitor neurological disorders. Aethlon is part of the Russell Microcap® Index. Additional information can be found online at www.AethlonMedical.com or you can connect with us on Twitter, LinkedIn, Facebook and Google+. 

About Dr. Van Keuren-Jensen and TGen Dr. Kendall Van Keuren-Jensen is a neurobiologist with the Phoenix-based Translational Genomics Research Institute (TGen). Translational Genomics Research Institute (TGen), a non-profit biomedical research organization, focuses on medical advancements through cutting edge translational processes. Working with collaborators in the scientific and medical communities, TGen makes a substantial contribution to both the scientific and medical fields. For additional information, visit https://www.tgen.org

Health Clipboard

Health Clipboard

Health news and discoveries in San Diego. Marilyn Hyder hosts weekdays on KOGO AM! Read more


Content Goes Here